Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | RGS12 | O14924 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.30 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
| ▸ | THPO | P40225 | 1/20 | 0.30 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL96784 | 0.91 | — | — | |
| SCHEMBL28095746 | 0.91 | TSHR (0.41) | TSHR | |
| SCHEMBL27943295 | 0.88 | — | — | |
| Hydrochloric Acid SCHEMBL15993889 | 0.88 | — | — | |
| Water SCHEMBL27585514 | 0.88 | — | — | |
| SCHEMBL17923723 | 0.88 | — | — | |
| SCHEMBL27832790 | 0.88 | — | — | |
| SCHEMBL27740486 | 0.88 | — | — | |
| Ethane SCHEMBL27890282 | 0.88 | — | — | |
| Acetic Acid SCHEMBL8850219 | 0.78 | FFAR3 (0.37) | TSHRCYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030202951-A1 | Method for reducing the appearance of dark circles under the eyes | COLE CURTIS (US) | 2003-10-30 | — | — | US | claimed |
| US-6680122-B2 | ELECTRODEPOSITION OF PAINT | KANSAI PAINT CO., LTD. (JP) | 2004-01-20 | — | — | US | disclosed |
| US-20020119318-A1 | Cationic paint composition | KANSAI PAINT CO., LTD. (JP) | 2002-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030202951-A1 | Method for reducing the appearance of dark circles under the eyes | AOC3, ACOX3, AOC2 | TSHR 3418/4885CHRM2 257/4885ADRA1A 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.